DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for toxoplasmosis — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleToxoplasmosis maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for toxoplasmosis is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
tumor necrosis factor (TNF) — TNF is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet apo structuredrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 5YOY · 2.727 Å · ligand none (apo structure). Experimental structure, not a prediction.
What the evidence adds up to
The dihydrotriazine JPC-2067-B, the active metabolite of the prodrug JPC-2056, inhibits Toxoplasma gondii growth in culture with an IC50 of 20 nM and inhibits the purified T. gondii dihydrofolate reductase enzyme with an IC50 of 6.5 nM. In these in vitro assays it was more efficacious than pyrimethamine and was cidal. Parenterally administered JPC-2067-B and orally administered JPC-2056 were also effective against T. gondii tachyzoites in vivo. The three main parasite clonal types and isolates from South and Central America, the United States, Canada, China, and Sri Lanka share the same amino acid sequences at the key binding sites for the triazine. These findings come from a single 2008 study; no subsequent human trials of JPC-2056 or JPC-2067-B for toxoplasmosis are reported in the provided abstracts.
A 2025 systematic review of toxoplasmosis cases in patients receiving targeted immunotherapy with biologics or small molecules was conducted, but the abstract provides no numerical results, no case counts, and no treatment outcomes. The review’s stated goal was to extract clinical presentations, diagnostic findings, and treatment details, and to offer prevention and management recommendations, but the abstract itself contains none of that data.
A 1961 monograph summarises a 1956 paediatric conference on toxoplasmosis, with contributions from 12 countries and an introductory discussion by Albert B. Sabin. It is a historical compilation of then-current knowledge, not a source of new experimental or clinical data.
What is still missing: a human clinical trial of JPC-2056 or JPC-2067-B for toxoplasmosis, any controlled efficacy data in patients, and a clear patient stratification strategy for those who might benefit. The 2025 systematic review’s full results are not given, so the actual burden and management of toxoplasmosis in immunotherapy patients remains unquantified in these abstracts. Funding for a phase 2 trial of the triazine compounds in toxoplasmosis has not been reported.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Novel Triazine JPC-2067-B Inhibits Toxoplasma gondii In Vitro and In Vivo
AbstractBACKGROUND AND METHODOLOGY: Toxoplasma gondii causes substantial morbidity, mortality, and costs for healthcare in the developed and developing world. Current medicines are not well tolerated and cause hypersensitivity reactions. The dihydrotriazine JPC-2067-B (4, 6-diamino-1, 2-dihydro-2, 2-dimethyl-1-(3'(2-chloro-, 4-trifluoromethoxyphenoxy)propyloxy)-1, 3, 5-triazine), which inhibits dihydrofolate reductase (DHFR), is highly effective against Plasmodium falciparum, Plasmodium vivax, and apicomplexans related to T. gondii. JPC-2067-B is the primary metabolite of the orally active biguanide JPC-2056 1-(3'-(2-chloro-4-trifluoromethoxyphenyloxy)propyl oxy)- 5-isopropylbiguanide, which is being advanced to clinical trials for malaria. Efficacy of the prodrug JPC-2056 and the active metabolite JPC-2067-B against T. gondii and T. gondii DHFR as well as toxicity toward mammalian cells were tested. PRINCIPAL FINDINGS AND CONCLUSIONS: Herein, we found that JPC-2067-B is highly effective against T. gondii. We demonstrate that JPC-2067-B inhibits T. gondii growth in culture (IC50 20 nM), inhibits the purified enzyme (IC50 6.5 nM), is more efficacious than pyrimethamine, and is cidal in vitro. JPC-2067-B administered parenterally and the orally administered pro-drug (JPC-2056) are also effective against T. gondii tachyzoites in vivo. A molecular model of T. gondii DHFR-TS complexed with JPC-2067-B was developed. We found that the three main parasite clonal types and isolates from South and Central America, the United States, Canada, China, and Sri Lanka have the same amino acid sequences preserving key binding sites for the triazine. SIGNIFICANCE: JPC-2056/JPC-2067-B have potential to be more effective and possibly less toxic treatments for toxoplasmosis than currently available medicines.
Toxoplasmosis in the Era of Targeted Immunotherapy: A Systematic Review of Emerging Cases Linked to Biologics and Small Molecules in Autoimmune Diseases, Oncology and Transplantation
AbstractWe performed a systematic review of toxoplasmosis cases in patients receiving targeted immunotherapy with biologics or small molecules. Our goal is to extract details on the clinical presentations, diagnostic findings, and treatment of toxoplasmosis cases in patients on immunotherapy, and provide recommendations for the prevention and management of toxoplasmosis in patients receiving biologics or small molecules.
Open Science Framework · 2025 · 0 citations · open access
Toxoplasmosis in the Era of Targeted Immunotherapy: A Systematic Review of Emerging Cases Linked to Biologics and Small Molecules in Autoimmune Diseases, Oncology and Transplantation
AbstractWe performed a systematic review of toxoplasmosis cases in patients receiving targeted immunotherapy with biologics or small molecules. Our goal is to extract details on the clinical presentations, diagnostic findings, and treatment of toxoplasmosis cases in patients on immunotherapy, and provide recommendations for the prevention and management of toxoplasmosis in patients receiving biologics or small molecules.
Human Toxoplasmosis: Proceedings of the Conference on Clinical Aspects and Diagnostic Problems of Toxoplamosis in Pediatrics at the VIII International Congress of Paediatrics, Copenhagen
AbstractThis Conference, organized by the editor and participated in by representatives from 12 countries, was the largest meeting ever to be concerned with this subject. Although the Conference was held in 1956, the material presented was revised by the contributors in 1959. Thus, the monograph probably represents the greatest amount of information available on the subject of toxoplasmosis in a single volume. Following some prefatory remarks by Prof. P. Plum, there is an introductory discussion, by Dr. Albert B. Sabin, of the status of problems posed by toxoplasmosis in pediatrics. There then follow six sections, each made up of contributions by participants from various countries.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
